NEOG — Neogen Corporation

NEOG Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $209 million, up 0.3% year-over-year on a core basis.
• Adjusted EBITDA: $35.5 million, representing a margin of 17%.
• Adjusted Net Income: $9 million, or $0.04 per share, down from $14 million and $0.07 in the prior year.
• Free Cash Flow: Outflow of $13 million, an improvement of $43 million compared to the prior year, driven by lower CapEx and better working capital efficiency.
• Gross Margin: 45.4%, showing sequential improvement but impacted by inventory write-offs and higher operating expenses.

2. Strategic Updates and Business Highlights

• New CEO Mike Nassif emphasized the need for operational and financial improvement, focusing on top-line growth, cost management, innovation, and deleveraging.
• A global headcount reduction of approximately 10% is expected to reduce operating expenses by $20 million annually, with some reinvestment planned for growth initiatives.
• The company is optimizing its product portfolio and targeting higher growth markets, particularly in the U.S.
• Significant efforts are underway to improve the PetriFilm production process, with initial testing showing promising results.
• The integration of the sample collection product line is being prioritized to address cash flow challenges.

3. Forward Guidance and Outlook

• Neogen reaffirmed its full-year guidance for fiscal 2026, anticipating a modest sequential revenue increase in Q2.
• The company expects improved EBITDA margins as operational efficiencies are realized and cost reductions take effect.
• Management is optimistic about future revenue growth driven by enhanced commercial efforts and innovation focus.

4. Bad News, Challenges, or Points of Concern

• Market Share Losses: Neogen has experienced share losses in key product lines, particularly in sample collection and allergens, attributed to execution challenges and supply chain issues.
• PetriFilm Decline: The product line saw a mid-single-digit revenue decline, which management believes is temporary due to distributor changes.
• Inventory Management Issues: Elevated inventory write-offs and spoilage remain a concern, with excess inventory tying up cash.
• Operational Inefficiencies: Challenges in sample collection production have resulted in higher costs and negative cash flow, although improvements are expected.

5. Notable Q&A Insights

• CEO Mike Nassif expressed confidence in Neogen's potential, citing a strong employee commitment and a broad product portfolio in an attractive market.
• Nassif highlighted the need for improved execution and accountability to regain market share and drive growth.
• CFO Dave Naemura provided clarity on the impact of inventory and operational challenges on margins, indicating a path toward recovery as improvements are implemented.
• The company is continuously evaluating its portfolio for optimization opportunities, with a focus on food safety and animal safety products.

Overall, while Neogen faces significant operational challenges and market share losses, the new leadership is committed to a focused strategy aimed at driving growth and improving financial performance.